Cargando…

2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics

BACKGROUND: Delays in appropriate therapy of infections affect clinical outcomes. The aim of this study was to compare the clinical and economic outcomes of patients with cUTI and cIAI due to cephalosporin- and carbapenem-resistant GNOs to similar infections caused by nonresistant GNOs. METHODS: A r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hercilla, Luis, Perez, Giancarlo, Illescas, Ricardo, Hidalgo, Jose, Ramirez, Eresvita, Moreno, Vanesa, Galdos-Cardenas, Gerson, Gutierrez-Rodriguez, Raul, Rodriguez, Lourdes, Carlos Orengo, Juan, Monsanto, Homero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809546/ http://dx.doi.org/10.1093/ofid/ofz360.1715

Ejemplares similares

260 Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae
por: Popejoy, Myra, et al.
Publicado: (2014)

Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain
por: Ferrer, Ricard, et al.
Publicado: (2021)

An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients
por: Gatti, Milo, et al.
Publicado: (2021)

492 Complicated Intra-abdominal Infection (cIAI) and 30-day Hospital Readmission
por: Furuno, Jon P., et al.
Publicado: (2014)

223. Development and Analysis of a Novel DOOR Endpoint for Complicated Intra-abdominal Infections (cIAI) Using 10 Registrational Trials for Antibacterial Drugs
por: Kinamon, Tori, et al.
Publicado: (2022)

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)
por: Aronin, Steven I, et al.
Publicado: (2023)

2264. An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset (CO) “Low-Risk” (LR) Complicated Intra-Abdominal Infections (cIAI) Across US Hospitals
por: Lodise, Thomas, et al.
Publicado: (2019)

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
por: Solomkin, Joseph, et al.
Publicado: (2015)

874 Risk Factors for Complicated Urinary Tract Infection (cUTI) due to Pseudomonas
por: Mcgregor, Jessina C., et al.
Publicado: (2014)

1044 Efficacy of Ceftolozane/Tazobactam vs Levofloxacin in the Treatment of Complicated Urinary Tract Infections (cUTI) caused by Levofloxacin-resistant Pathogens: Results from the ASPECT-cUTI Trial
por: Sakoulas, George, et al.
Publicado: (2014)

1031 Comparative Epidemiology of Complicated Urinary Tract Infections (cUTI) by Age among US Hospitals
por: Mocarski, Michelle, et al.
Publicado: (2014)

1673. Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US)
por: Lodise, Thomas, et al.
Publicado: (2020)

Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation
por: Portsmouth, Simon, et al.
Publicado: (2021)

1040 Describing Antibiotic Utilization Patterns and Healthcare Costs for Ambulatory and Inpatient/ED Treatment of Complicated Urinary Tract Infection (cUTI)
por: Karve, Sudeep, et al.
Publicado: (2014)

IAI NUPECC
Publicado: (2001)

1473. Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes vs. Investigator’s Evaluation in the APEKS-cUTI Study
por: Portsmouth, Simon, et al.
Publicado: (2019)

666. Efficacy and Safety of Cefiderocol According to Renal Impairment in Patients With Complicated Urinary Tract Infection (cUTI) in a Phase 2 Study
por: Portsmouth, Simon, et al.
Publicado: (2019)

Genotypic characteristics of Uropathogenic Escherichia coli isolated from complicated urinary tract infection (cUTI) and asymptomatic bacteriuria—a relational analysis
por: Maniam, Lalitha, et al.
Publicado: (2023)

1521. Heterogeneity of Recent Phase 3 cUTI Clinical Trials with New Antibiotics
por: Bass, Almasa, et al.
Publicado: (2018)

1430. Descriptive Epidemiology of Emergency Department Visits with cUTI in the US, 2012-2018
por: Zilberberg, Marya, et al.
Publicado: (2021)

1670. Clinical Characteristics and Demographics of Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
por: Sulham, Katherine, et al.
Publicado: (2020)

1682. Health Resource Utilization in Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
por: Sulham, Katherine, et al.
Publicado: (2020)

2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI)
por: Dorr, Mary Beth, et al.
Publicado: (2023)

2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study
por: Moeck, Greg, et al.
Publicado: (2023)

124. Microbiological Outcomes With Plazomicin (PLZ) Versus Meropenem (MEM) in Patients With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in the EPIC Study
por: Keepers, Tiffany R, et al.
Publicado: (2018)

Improving the EMI shielding of graphene oxide (GNO)-coated glass-fiber–GNO–MA-grafted polypropylene (PP) composites and nylon 1D–2D nanocomposite foams
por: Raagulan, Kanthasamy, et al.
Publicado: (2022)

1683. Hospital Admission Patterns in Adult Patients with Complicated Urinary Tract Infections (cUTIs): Identification of Potentially Avoidable Hospital Admissions Across United States (US) Hospitals
por: Lodise, Thomas, et al.
Publicado: (2020)

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
por: McGovern, Paul C, et al.
Publicado: (2022)

1578. Treatments for complicated urinary tract infections (cUTI) caused by multidrug resistant (MDR) Gram-negative (GN) pathogens- a systematic review and network meta-analysis (NMA)
por: Reason, Tim, et al.
Publicado: (2020)

Stenotrophomonas maltophilia: Complicating treatment of ESBL UTI
por: Kumar, Simit, et al.
Publicado: (2015)

Host Immune Regulation in Implant-Associated Infection (IAI): What Does the Current Evidence Provide Us to Prevent or Treat IAI?
por: Maimaiti, Zulipikaer, et al.
Publicado: (2023)

LB-3. Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study
por: Muir, Lori A, et al.
Publicado: (2020)

Calcinosis Cutis as an Unsuspecting Complication of Hyperkalemia Treatment
por: Gresham, Lauren N, et al.
Publicado: (2021)

637. Treatment Outcomes in Secondary Analysis Populations of Adult Patients the ALLIUM Phase 3 study Comparing Cefepime-Enmetazobactam to Piperacillin-Tazobactam for Complicated Urinary Tract Infections (cUTI) or Acute Pyelonephritis (AP)
por: Kaye, Keith S, et al.
Publicado: (2021)

Science publishing 2035
por: Higgitt, Rebekah
Publicado: (2016)

1477. A Randomized Phase 2 Study of Cefepime Combined with the Novel Extended Spectrum β-Lactamase Inhibitor Enmetazobactam in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP)
por: Carmeli, Yehuda, et al.
Publicado: (2019)

720. Efficacy of Fosfomycin for Injection (FOS) vs. Piperacillin–Tazobactam (PIP-TAZ) in Adults with Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): ZEUS Study Outcomes in Patients With Reduced Study Drug Susceptibility
por: Kaye, Keith S, et al.
Publicado: (2019)

Phage Therapy in the Year 2035
por: Pirnay, Jean-Paul
Publicado: (2020)

Calcinosis cutis: a rare complication of chronic myeloid leukemia
por: Samdani, Azam
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ujhoeoaq344p7os7s9toslcbri